A Study of Jyseleca Tablet (Filgotinib Maleate) in Korean Participants
Post Marketing Surveillance of Jyseleca Tab. (Filgotinib Maleate) in Korean Subjects
Eisai Korea Inc.
2,040 participants
Feb 27, 2024
OBSERVATIONAL
Conditions
Summary
The purpose of this study is to collect and evaluate the following information in relation to the safety and the efficacy of Jyseleca tablet (Filgotinib Maleate) 100 milligram (mg) and 200 mg in this post marketing setting: (1) Serious adverse events and adverse drug reactions (2) Unexpected adverse events and adverse drug reactions not reflected in precautions for use (3) Known adverse drug reactions (4) Non-serious adverse events and adverse drug reactions (5) Other safety and effectiveness related information will be evaluated in accordance with the permitted articles under the actual conditions of use in Korea.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
No intervention will be administered.
Locations(64)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06246123